newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

  • Nebokitug Phase 3 trial design is near completion following positive feedback from the FDA & EMA, which support a single registration trial using a clinical event composite endpoint.
  • Data from the Phase 2 SPRING trial open-label extension presented at AASLD 2025 showed favorable safety & consistent improvements in key biomarkers for up to 48 weeks.
  • New clinical data presented at AASLD 2025 provided insights into nebokitug's direct macrophage-mediated mechanisms relevant to halting or slowing PSC disease progression.
  • The company is advancing multiple partnering options to support the Phase 3 program while expecting its cash runway to extend through the end of Q4 2026.
  • Cash, cash equivalents, & short-term bank deposits totaled $10.2 million as of September 30, 2025, down from $14.2 million in December 2024.
  • Research & development expenses for Q3 2025 were approximately $1 million, a decrease from $2.8 million in Q3 2024 due to the end of SPRING trial activities.
  • General & administrative expenses for Q3 2025 were approximately $0.9 million, remaining equivalent to the prior year's quarter.
  • Net loss for Q3 2025 was $1.7 million, or less than half a cent per share, compared to $3.5 million in Q3 2024.
  • An ADS reverse split effective August 26, 2025, changed the ratio from one ADS to 20 Class A ordinary shares to one ADS to 80 Class A ordinary shares.
  • As of September 30, 2025, the company had 492,409,320 ordinary shares issued & outstanding, equivalent to 6,155,117 ADSs.